6.7.1 Bromocriptine and other dopaminergic drugs

These drugs are indicated for the inhibition of prolactin release.  Refer to chapter 4.9 for their use in Parkinson's disease.

MHRA Safety Update: Ergot-derived dopamine agonists: risk of fibrotic reactions

8 tablet
  • First Line Drugs
  • Second Line Drugs
  • Specialist Initiated Drugs with Shared Care Guidelines
  • Specialist Only Drugs
  • Mixed Status